Vandetanib is an antineoplastic kinase inhibitor used to treat symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
- Mechanism
- Curator reviewed
ZD-6474 is a potent and selective inhibitor of VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor) and RET (REarranged during Transfection) tyrosine kinases.
VEGFR- and EGFR-dependent signalling are both clinically validated pathways in cancer, including non-small-cell lung cancer (NSCLC). RET activity is important in some types of thyroid cancer, and early data with vandetanib in medullary thyroid cancer has led to orphan-drug designation by the regulatory authorities in the USA and EU.
- Primary indication
- Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease.Curator reviewed · 2 structured indications
- Formula / weight
- C22H24BrFN4O2 · 475.354 g/mol (avg)
- First approval
- Canada, 2024 · United States, 2011 · European Union, 2016
- Code names
- GNF-PF-2188 · HSDB 8198 · SAR390530 · ZD-6474
- Brand names
Resolves to
UHTHHESEBZOYNR-UHFFFAOYSA-NSMILESCOC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1What you can answer from here — as of June 15, 2026
Which drugs share a target with Vandetanib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account